Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats.
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Rat models of immobilization-induced osteopenia are characterized by uncoupling of bone metabolism, i.e., increased bone resorption and decreased bone formation in trabecular bone. Using such a rat model, the efficacy of osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin, a novel secreted protein that inhibits osteoclastogenesis, in reducing bone loss was investigated. Male Fischer rats were neurectomized and injected intramuscularly with either OCIF (0.2, 1.0, or 5.0 mg/kg body weight) or vehicle once daily for 7 days. On the eighth day after sciatic neurectomy, significant bone loss was observed in the vehicle-injected rats. OCIF ameliorated the decrease in bone mineral density (BMD) of both the proximal and distal femur in a dose-dependent manner. OCIF also ameliorated the decrease in bone strength of the femoral neck at the highest dose. A high correlation (r = 0.805) was detected between the BMD of the distal femur and the bone strength of the femoral neck. When OCIF was administered intermittently to the immobilized rats twice weekly (on days 1 and 4) after immobilization, it also ameliorated the decrease in BMD of the distal femur. These results suggest that OCIF has therapeutic potential for the treatment of immobilization-induced osteopenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This study showed strong correlations between femur BMD and femoral neck strength, consistent with the preservation of bone quality and improvements in bone mass (292).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [292]
In the citing paper
“OPG also prevented decreases in BMD and bone strength in a rat sciatic neurectomy model.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [292]
In the citing paper
“OPG treatment of neurectomized rats improved BMD and bone strength at the femoral neck (292).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [292]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · cited 9×
“The observations that OCIF specifically acts on bone tissue and is involved in the regulation of bone metabolism are consistent with those in the OCIF/OPG-treated OVX model and in normal rats [4,5].”
BackgroundInfluentialOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · cited 13×
“The observations that OCIF specifically acts on bone tissue and is involved in the regulation of bone metabolism are consistent with those in the OCIF/OPG-treated OVX model and in normal rats [4,5].”
BackgroundResultInfluentialYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228 · cited 9×
“The observations that OCIF specifically acts on bone tissue and is involved in the regulation of bone metabolism are consistent with those in the OCIF/OPG-treated OVX model and in normal rats [4,5].”
BackgroundInfluentialSelf-citationYasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201 · cited 3×
“The observations that OCIF specifically acts on bone tissue and is involved in the regulation of bone metabolism are consistent with those in the OCIF/OPG-treated OVX model and in normal rats [4,5].”
BackgroundResultSelf-citationIsolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.
Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787 · cited 1×
“We previously purified osteoclastogenesis inhibitory factor (OCIF) from the conditioned medium of human embryonic lung fibroblasts, IMR-90 [3].”
MethodSelf-citationRANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746 · cited 6×
“Recent studies on ODF revealed that it stimulates multiple steps regulating osteoclast function such as recruitment, activation, and survival in vitro [7–12], and that RANK, a member of the TNF receptor family, is the essential signaling receptor for ODF [13].”
BackgroundInfluentialSelf-citationFuller, K., Wong, B., Fox, S., Choi, Y., & Chambers, T. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.5.997 · Cited by 561 · cited 1×
“Recent studies on ODF revealed that it stimulates multiple steps regulating osteoclast function such as recruitment, activation, and survival in vitro [7–12], and that RANK, a member of the TNF receptor family, is the essential signaling receptor for ODF [13].”
BackgroundAdvances in Bone Biology: The Osteoclast*
ROODMAN, G. D. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-4-308 · Cited by 549 · cited 1×
“The process of bone remodeling is controlled under a balance of bone formation by osteoblasts and bone resorption by osteoclasts [1].”
BackgroundMatsuzaki, K., Udagawa, N., Takahashi, N., Yamaguchi, K., Yasuda, H., Shima, N., Morinaga, T., Toyama, Y., Yabe, Y., Higashio, K., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8586 · Cited by 338 · cited 1×
“Recent studies on ODF revealed that it stimulates multiple steps regulating osteoclast function such as recruitment, activation, and survival in vitro [7–12], and that RANK, a member of the TNF receptor family, is the essential signaling receptor for ODF [13].”
BackgroundSelf-citationWeinreb, M., Rodan, G. A., & Thompson, D. D. (1989) · Bone · doi:10.1016/8756-3282(89)90052-5 · Cited by 289 · cited 2×
“In addition, immobilization-induced osteopenia is characterized by both a decrease in the bone formation rate and an increase in the bone resorption rate, resulting in rapid bone loss [20].”
Background
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Lewiecki, E. M., Miller, P. D., McClung, M. R., Cohen, S. B., Bolognese, M. A., Liu, Y., Wang, A., Siddhanti, S., & Fitzpatrick, L. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070809 · Cited by 319
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281
The OPG/RANKL/RANK system in metabolic bone diseases.
Hofbauer, L. C., Kühne, C. A., & Viereck, V. (2004) · PubMed · Cited by 316
Kondegowda, N. G., Fenutria, R., Pollack, I. R., Orthofer, M., Garcia-Ocaña, A., Penninger, J. M., & Vasavada, R. C. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.021 · Cited by 169
“Injecting human OPG in rats generates antibodies against the human peptide (Mochizuki et al., 2002).”
Delmas, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.02.002 · Cited by 131
Maïmoun, L., Couret, I., Mariano‐Goulart, D., Dupuy, A., Micallef, J., Péruchon, E., Ohanna, F., Cristol, J., Rossi, M., & Leroux, J. L. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0048-6 · Cited by 97
“reduced the immobilization-induced osteopenia in rats with sciatic neurectomy [ 19 ] and improved the femoral mechanical properties in tail-suspended mice [20], the OPG/RANKL system could be implicated in the immobilization-related osteoporosis in patients with SCI.”
BackgroundVerdrengh, M., Bokarewa, M. I., Ohlsson, C., Stolina, M., & Tarkowski, A. (2009) · Bone · doi:10.1016/j.bone.2009.10.028 · Cited by 33
Direct effects of osteoprotegerin on human bone cell metabolism
Grundt, A., Grafe, I., Liegibel, U. M., Sommer, U., Nawroth, P. P., & Kasperk, C. H. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.026 · Cited by 34
Positioning novel biologicals in CKD-mineral and bone disorders
Tartaglione, L., Pasquali, M., Rotondi, S., Muci, M. L., Covic, A. C., & Mazzaferro, S. (2017) · Journal of Nephrology · doi:10.1007/s40620-017-0410-1 · Cited by 19
“In animal models of OP [42] or of glucocorticoid-induced OP [43], RANK-L inhibition reduced bone loss and increased BMD.”
BackgroundStrategic approaches to osteoporosis in transplantation
Mattano, L. A. (2004) · Pediatric Transplantation · doi:10.1111/j.1398-2265.2004.00184.x · Cited by 16
“Interestingly, decreased OPG levels correlated with osteoporosis in a rat model of immobilization (37).”
BackgroundHuang, B., Zhu, W., Zhao, H., Zeng, F., Wang, E., Wang, H., Chen, J., Li, M., Huang, C., Ren, L., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.563509 · Cited by 13
Treatment of immobilization-related hypercalcaemia with denosumab
Malberti, F. (2012) · Clinical Kidney Journal · doi:10.1093/ckj/sfs133 · Cited by 13
“OPG administration by inhibiting osteoclast activity ameliorates the decrease in both bone mineral density and bone strength in immobilized rats [29].”
BackgroundBauman, W. A., & Cardozo, C. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00047-9 · Cited by 14
Saito-Yabe, M., Kasuya, Y., Yoshigae, Y., Yamamura, N., Suzuki, Y., Fukuda, N., Honma, M., Yano, K., Mochizuki, S.-I., Okada, F., et al. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01120.x · Cited by 8
“previous study that OCIF increased BMD and bone strength in a rat model of immobilization-induced osteopenia by a daily, or twice a week, intramuscular administration.([24]) It was also reported that OCIF improved bone volume and bone strength in a tail-suspended growing rat model by daily intra-muscular administratio…”
BackgroundSelf-citationMiyaji, Y., Kurihara, A., Kamiyama, E., Shiiki, T., Kawai, K., & Okazaki, O. (2009) · Xenobiotica · doi:10.1080/00498250802590745 · Cited by 7
“…of full-length rhOPG, which is abbreviated as rhOPG in the present study, effectively increases the bone mineral density of normal rats at a dose of 3 mg kg−1 once daily for 14 days (Yasuda et al. 1998b) and in immobilized rats at a dose of 0.2 mg kg−1 once daily for 7 days (Mochizuki et al. 2002).”
MethodInfluentialPhysiopathology of cancer metastases in bone and of the changes they induce in bone remodeling
BONUCCI, E. (2002) · RENDICONTI LINCEI · doi:10.1007/bf02904492 · Cited by 5
“OPG administration reduces the degree of immobilization osteopenia in femurs of sciatic neurectomized rats (Mochizuki et al., 2002), reduces bone erosion and osteoclast numbers in TNF-α transgenic mice (Redlich et al.”
BackgroundCardozo, C. P., & Bauman, W. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00040-x · Cited by 6
Die Rolle von RANK-Ligand und Osteoprotegerin bei Osteoporose
Hofbauer, L. C. (2004) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 4
Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel
Hofbauer, L. C., & Schoppet, M. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_21 · Cited by 1
Osteoporosis Therapy: Mechanistic Antiresorptives
Dodge, J. A., & Bryant, H. U. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc197
Osteoporosis and sarcopenia in older adults
Chalhoub, D. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Kendler, D. L. (2010) · Orthopedic Research and Reviews · doi:10.2147/orr.s6124
Osteoporosis Therapy: Mechanistic Antiresorptives
Dodge, J. A., & Bryant, H. U. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc197.pub2 · Cited by 1
Metadata
- Authors
- Mochizuki, S.-I., Fujise, N., Higashio, K., & Tsuda, E.
- Affiliations
- Megmilk Snow Brand (Japan) (JP)
- Venue
- Journal of Bone and Mineral Metabolism
- Published
- 2002-01-01
- Volume
- 20
- Issue
- 1
- Pages
- 14-20
- ISSN
- 0914-8779 (ISSN-L)
- 1435-5604
- OpenAlex
- W1998829944
- Cited by
- 24
- References
- 20
- Citations by year
- 2021: 1 · 2020: 2 · 2017: 1 · 2015: 2 · 2013: 1 · 2012: 1
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Bone and Mineral Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Physiology (medical) › Spaceflight effects on biology
- Keywords
- osteoprotegerin, bone mineral density, bone strength, femoral neck, femur, sciatic neurectomy, bone resorption, bone formation, trabecular bone, bone loss treatment
- MeSH terms
- Animals, Body Weight, Bone Resorption, Dose-Response Relationship, Drug, Femur, Glycoproteins, Injections, Intramuscular, Male, Rats, Inbred F344, Restraint, Physical, Sciatic Nerve, Bone Density, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Rats, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.